410PPhase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis

A.J. Olszanski; R. Gonzalez; P. Corrie; A.C. Pavlick; M. Middleton; P. Lorigan; R. Plummer; S. Skaria; C. Herbert; M. Gore; S. Agarwala; A. Daud; S. Zhang; B. Bahamon; L. Rangachari; E. Hoberman; M. Kneissl; D. Rasco

doi:10.1093/annonc/mdx367.043

410PPhase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis

A.J. Olszanski, R. Gonzalez, P. Corrie, A.C. Pavlick, M. Middleton, P. Lorigan, R. Plummer, S. Skaria, C. Herbert, M. Gore, S. Agarwala, A. Daud, S. Zhang, B. Bahamon, L. Rangachari, E. Hoberman, M. Kneissl, D. Rasco

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Annals of Oncology
Volume	28
Issue number	suppl_5
DOIs	https://doi.org/10.1093/annonc/mdx367.043
Publication status	Published - 1 Sept 2017

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdx367.043

Cite this

Olszanski, A. J., Gonzalez, R., Corrie, P., Pavlick, A. C., Middleton, M., Lorigan, P., Plummer, R., Skaria, S., Herbert, C., Gore, M., Agarwala, S., Daud, A., Zhang, S., Bahamon, B., Rangachari, L., Hoberman, E., Kneissl, M., & Rasco, D. (2017). 410PPhase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis. Annals of Oncology, 28(suppl_5). https://doi.org/10.1093/annonc/mdx367.043

@article{4e39798aa0eb4db0a4228021b8d2a4e7,

title = "410PPhase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis",

author = "A.J. Olszanski and R. Gonzalez and P. Corrie and A.C. Pavlick and M. Middleton and P. Lorigan and R. Plummer and S. Skaria and C. Herbert and M. Gore and S. Agarwala and A. Daud and S. Zhang and B. Bahamon and L. Rangachari and E. Hoberman and M. Kneissl and D. Rasco",

year = "2017",

month = sep,

day = "1",

doi = "10.1093/annonc/mdx367.043",

language = "English",

volume = "28",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier BV",

number = "suppl_5",

}

Olszanski, AJ, Gonzalez, R, Corrie, P, Pavlick, AC, Middleton, M, Lorigan, P, Plummer, R, Skaria, S, Herbert, C, Gore, M, Agarwala, S, Daud, A, Zhang, S, Bahamon, B, Rangachari, L, Hoberman, E, Kneissl, M & Rasco, D 2017, '410PPhase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis', Annals of Oncology, vol. 28, no. suppl_5. https://doi.org/10.1093/annonc/mdx367.043

TY - JOUR

T1 - 410PPhase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis

AU - Olszanski, A.J.

AU - Gonzalez, R.

AU - Corrie, P.

AU - Pavlick, A.C.

AU - Middleton, M.

AU - Lorigan, P.

AU - Plummer, R.

AU - Skaria, S.

AU - Herbert, C.

AU - Gore, M.

AU - Agarwala, S.

AU - Daud, A.

AU - Zhang, S.

AU - Bahamon, B.

AU - Rangachari, L.

AU - Hoberman, E.

AU - Kneissl, M.

AU - Rasco, D.

PY - 2017/9/1

Y1 - 2017/9/1

UR - http://www.mendeley.com/research/410pphase-i-study-investigational-oral-panraf-kinase-inhibitor-tak580-mln2480-patients-advanced-soli

U2 - 10.1093/annonc/mdx367.043

DO - 10.1093/annonc/mdx367.043

M3 - Article

SN - 0923-7534

VL - 28

JO - Annals of Oncology

JF - Annals of Oncology

IS - suppl_5

ER -

410PPhase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Cite this